Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment.

Tenero D, Derimanov G, Carlton A, Tonkyn J, Davies M, Cozens S, Gresham S, Gaudion A, Puri A, Muliaditan M, Rullas-Trincado J, Mendoza-Losana A, Skingsley A, Barros-Aguirre D.

Antimicrob Agents Chemother. 2019 Jul 25;63(8). pii: e00240-19. doi: 10.1128/AAC.00240-19. Print 2019 Aug.

2.

A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects.

Okour M, Puri A, Chen G, Port K, Berni A, Khindri S, Schneider I, Tenero D.

Clin Ther. 2019 Jun;41(6):1110-1127. doi: 10.1016/j.clinthera.2019.04.007. Epub 2019 May 4.

PMID:
31060740
3.

A population analysis of the DGAT1 inhibitor GSK3008356 and its effect on endogenous and meal-induced triglyceride turnover in healthy subjects.

Okour M, Brigandi RA, Tenero D.

Fundam Clin Pharmacol. 2019 Oct;33(5):567-580. doi: 10.1111/fcp.12455. Epub 2019 Mar 7.

PMID:
30790345
4.

Pharmacokinetics, Safety, and Tolerability Evaluation of Single and Multiple Doses of GSK3342830 in Healthy Volunteers.

Tenero D, Farinola N, Berkowitz EM, Tiffany CA, Qian Y, Xue Z, Raychaudhuri A, Gardiner DF.

Clin Pharmacol Drug Dev. 2019 Aug;8(6):754-764. doi: 10.1002/cpdd.637. Epub 2018 Dec 10.

PMID:
30536589
5.

Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial.

Thakkar N, Green JA, Koh GCKW, Duparc S, Tenero D, Goyal N.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e00711-18. doi: 10.1128/AAC.00711-18. Print 2018 Nov.

6.

The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects.

Caltabiano S, Mahar KM, Lister K, Tenero D, Ravindranath R, Cizman B, Cobitz AR.

Pharmacol Res Perspect. 2018 Mar 9;6(2):e00327. doi: 10.1002/prp2.327. eCollection 2018 Apr.

7.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model.

VanScoy BD, Tenero D, Turner S, Livermore DM, McCauley J, Conde H, Bhavnani SM, Rubino CM, Ambrose PG.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01052-17. doi: 10.1128/AAC.01052-17. Print 2017 Dec.

8.

Exposure-Response Analyses for Tafenoquine after Administration to Patients with Plasmodium vivax Malaria.

Tenero D, Green JA, Goyal N.

Antimicrob Agents Chemother. 2015 Oct;59(10):6188-94. doi: 10.1128/AAC.00718-15. Epub 2015 Jul 27.

9.

The challenge of antimicrobial resistance: new regulatory tools to support product development.

Tomayko JF, Rex JH, Tenero DM, Goldberger M, Eisenstein BI.

Clin Pharmacol Ther. 2014 Aug;96(2):166-8. doi: 10.1038/clpt.2014.107. Epub 2014 May 13. Review.

PMID:
24823890
10.

Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteers.

Tenero D, Bowers G, Rodvold KA, Patel A, Kurtinecz M, Dumont E, Tomayko J, Patel P.

Antimicrob Agents Chemother. 2013 Jul;57(7):3334-9. doi: 10.1128/AAC.02483-12. Epub 2013 May 6.

11.

Disposition and metabolism of GSK2251052 in humans: a novel boron-containing antibiotic.

Bowers GD, Tenero D, Patel P, Huynh P, Sigafoos J, O'Mara K, Young GC, Dumont E, Cunningham E, Kurtinecz M, Stump P, Conde JJ, Chism JP, Reese MJ, Yueh YL, Tomayko JF.

Drug Metab Dispos. 2013 May;41(5):1070-81. doi: 10.1124/dmd.112.050153. Epub 2013 Feb 25.

PMID:
23439661
12.

Ethanol does not alter the pharmacokinetic profile of the controlled-release formulation of carvedilol.

Henderson LS, Tenero DM, Campanile AM, Baidoo CA, Danoff TM.

J Clin Pharmacol. 2007 Nov;47(11):1358-65.

PMID:
17962424
14.

Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.

Packer M, Lukas MA, Tenero DM, Baidoo CA, Greenberg BH; 369 Study Group.

Am J Cardiol. 2006 Oct 2;98(7A):39L-45L.

PMID:
17023231
15.

Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure.

Tenero DM, Henderson LS, Campanile AM, Baidoo CA, Boyle D.

Am J Cardiol. 2006 Oct 2;98(7A):27L-31L. Epub 2006 Aug 28.

PMID:
17023229
16.

Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.

Henderson LS, Tenero DM, Baidoo CA, Campanile AM, Harter AH, Boyle D, Danoff TM.

Am J Cardiol. 2006 Oct 2;98(7A):17L-26L. Epub 2006 Aug 28.

PMID:
17023228
17.

Pharmacokinetic properties of a new controlled-release formulation of carvedilol.

Tenero DM, Henderson LS, Baidoo CA, Harter AH, Campanile AM, Danoff TM, Boyle D.

Am J Cardiol. 2006 Oct 2;98(7A):5L-16L. Epub 2006 Aug 28. Review.

PMID:
17023227
18.

Investigation of the interaction between argatroban and acetaminophen, lidocaine, or digoxin.

Inglis AM, Sheth SB, Hursting MJ, Tenero DM, Graham AM, DiCicco RA.

Am J Health Syst Pharm. 2002 Jul 1;59(13):1258-66.

PMID:
12116891
19.

Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure.

Tenero D, Boike S, Boyle D, Ilson B, Fesniak HF, Brozena S, Jorkasky D.

J Clin Pharmacol. 2000 Aug;40(8):844-53.

PMID:
10934668
20.

The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency.

Gehr TW, Tenero DM, Boyle DA, Qian Y, Sica DA, Shusterman NH.

Eur J Clin Pharmacol. 1999 Jun;55(4):269-77.

PMID:
10424319
21.

Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease.

Kovacs SJ, Tenero DM, Martin DE, Ilson BE, Jorkasky DK.

Pharmacotherapy. 1999 May;19(5):612-9.

PMID:
10331824
22.

A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies.

Blum RA, Kazierad DJ, Tenero DM.

Pharmacotherapy. 1999 Apr;19(4 Pt 2):79S-85S. Review.

PMID:
10213526
23.

Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations.

Bottorff MB, Tenero DM.

Pharmacotherapy. 1999 Apr;19(4 Pt 2):73S-78S. Review.

PMID:
10213525
24.

Effect of age and gender on the pharmacokinetics of eprosartan.

Tenero DM, Martin DE, Miller AK, Ilson B, Boike SC, Zariffa N, Jorkasky DK.

Br J Clin Pharmacol. 1998 Sep;46(3):267-70.

25.

Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food.

Tenero D, Martin D, Ilson B, Jushchyshyn J, Boike S, Lundberg D, Zariffa N, Boyle D, Jorkasky D.

Biopharm Drug Dispos. 1998 Sep;19(6):351-6.

PMID:
9737815
26.

A dose proportionality study of eprosartan in healthy male volunteers.

Chapelsky MC, Martin DE, Tenero DM, Ilson BE, Boike SC, Etheredge R, Jorkasky DK.

J Clin Pharmacol. 1998 Jan;38(1):34-9.

PMID:
9597557
27.

Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.

Martin DE, Chapelsky MC, Ilson B, Tenero D, Boike SC, Zariffa N, Jorkasky DK.

J Clin Pharmacol. 1998 Feb;38(2):129-37.

PMID:
9549643
28.

Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers.

Tenero DM, Martin DE, Ilson BE, Boyle DA, Boike SC, Carr AM, Lundberg DE, Jorkasky DK.

Ann Pharmacother. 1998 Mar;32(3):304-8.

PMID:
9533060
29.

Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan.

Tenero D, Martin D, Chapelsky M, Ilson B, Boike S, Patterson S, Keogh J, Rodriguez S, Jorkasky D.

Pharmacotherapy. 1998 Jan-Feb;18(1):42-50.

PMID:
9469680
30.

Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers.

Kazierad DJ, Martin DE, Blum RA, Tenero DM, Ilson B, Boike SC, Etheredge R, Jorkasky DK.

Clin Pharmacol Ther. 1997 Oct;62(4):417-25.

PMID:
9357393
31.

Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers.

Martin DE, Tompson D, Boike SC, Tenero D, Ilson B, Citerone D, Jorkasky DK.

Br J Clin Pharmacol. 1997 Jun;43(6):661-4.

32.

Altered beta-adrenergic sensitivity and protein binding to 1-propranolol in the elderly.

Tenero DM, Bottorff MB, Burlew BS, Williams JB, Lalonde RL.

J Cardiovasc Pharmacol. 1990 Nov;16(5):702-7.

PMID:
1703590
33.

Effects of age on the protein binding and disposition of propranolol stereoisomers.

Lalonde RL, Tenero DM, Burlew BS, Herring VL, Bottorff MB.

Clin Pharmacol Ther. 1990 Apr;47(4):447-55.

PMID:
2328552
34.

Dilevalol: an overview of its clinical pharmacology and therapeutic use in hypertension.

Lalonde RL, Tenero DM, Kazierad DJ.

Pharmacotherapy. 1990;10(1):15-28. Review.

PMID:
2179899
35.

Pharmacokinetics and pharmacodynamics of dilevalol.

Tenero DM, Bottorff MB, Given BD, Kramer WG, Affrime MB, Patrick JE, Lalonde RL.

Clin Pharmacol Ther. 1989 Dec;46(6):648-56.

PMID:
2598569
36.

Comparative dosage and toxicity of heparin sodium in the treatment of patients with pulmonary embolism versus deep-vein thrombosis.

Tenero DM, Bell HE, Deitz PA, Bertino JS Jr.

Clin Pharm. 1989 Jan;8(1):40-3. No abstract available.

PMID:
2912663
37.

Nonlinear accumulation of propranolol enantiomers.

Lalonde RL, Bottorff MB, Straka RJ, Tenero DM, Pieper JA, Wainer IW.

Br J Clin Pharmacol. 1988 Jul;26(1):100-2.

Supplemental Content

Loading ...
Support Center